Glenmark Pharmaceuticals
₹1,636.75
-13.05 (-0.79%)
- Advice
- Hold
21 September, 2024 04:29 BSE: 532296
NSE: GLENMARKISIN: INE935A01035
Start SIP in Glenmark Pharmaceuticals
Start SIPGlenmark Pharmaceuticals Performance
Day Range
- Low 1,610
- High 1,674
52 Week Range
- Low 722
- High 1,770
- Open Price1,659
- Previous Close1,650
- Volume2923466
Glenmark Pharmaceuticals F&O
Glenmark Pharmaceuticals Financials
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 2,297 | 2,148 | 1,365 | 2,233 | 2,144 | 1,875 |
Operating Expenses Qtr Cr | 1,698 | 1,651 | 1,549 | 1,763 | 1,659 | 1,721 |
Operating Profit Qtr Cr | 631 | 497 | -184 | 471 | 485 | 218 |
Depreciation Qtr Cr | 53 | 52 | 51 | 50 | 49 | 47 |
Interest Qtr Cr | 15 | 83 | 74 | 58 | 62 | 59 |
Tax Qtr Cr | 165 | 1,681 | -55 | 87 | 120 | -176 |
Net Profit Qtr Cr | 454 | 4,614 | -20 | 302 | 272 | -137 |
Glenmark Pharmaceuticals Technicals
EMA & SMA
Current Price
₹1,636.75
-13.05 (-0.79%)
- Bullish Moving Average
- ___
- 7
- Bearish Moving Average
- ___
- 9
- 20 Day
- ₹1,674.88
- 50 Day
- ₹1,569.56
- 100 Day
- ₹1,412.98
- 200 Day
- ₹1,211.37
- 20 Day
- ₹1,702.64
- 50 Day
- ₹1,568.18
- 100 Day
- ₹1,362.32
- 200 Day
- ₹1,136.01
Glenmark Pharmaceuticals Resistance and Support
PIVOT
₹1,640.25
Resistance | |
---|---|
First Resistance | 1,670.50 |
Second Resistance | 1,704.25 |
Third Resistance | 1,734.50 |
RSI | 46.54 |
MFI | 34.77 |
MACD Single Line | 50.22 |
MACD | 30.07 |
Support | |
---|---|
First Support | 1,606.50 |
Second Support | 1,576.25 |
Third Supoort | 1,542.50 |
Glenmark Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 2,952,962 | 187,601,676 | 63.53 |
Week | 1,405,087 | 81,115,684 | 57.73 |
1 Month | 1,063,369 | 58,559,726 | 55.07 |
6 Month | 976,276 | 42,399,651 | 43.43 |
Glenmark Pharmaceuticals Result Highlights
Glenmark Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8220.66 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2023. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.Market Cap | 46,555 |
Sales | 8,076 |
Shares in Float | 14.96 |
No of funds | 285 |
Yield | 0.15 |
Book Value | 2.03 |
U/D Vol ratio | 2 |
LTDebt / Equity | 15 |
Alpha | 0.15 |
Beta | 1.03 |
Glenmark Pharmaceuticals Shareholding Pattern
Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
---|---|---|---|---|
Promoters | 46.65% | 46.64% | 46.65% | 46.65% |
Mutual Funds | 10.92% | 10.55% | 8.59% | 7.3% |
Insurance Companies | 1.95% | 2.25% | 1.68% | 2.44% |
Foreign Portfolio Investors | 20.98% | 21.38% | 23.71% | 24.79% |
Financial Institutions/ Banks | 0.08% | 0.14% | 0.2% | 0.2% |
Individual Investors | 14.58% | 14.83% | 14.78% | 14.84% |
Others | 4.84% | 4.21% | 4.39% | 3.78% |
Glenmark Pharmaceuticals Management
Name | Designation |
---|---|
Mr. Glenn Saldanha | Chairman & Managing Director |
Mrs. Cherylann Pinto | Executive Director - Corporate Affairs |
Mr. V S Mani | Executive Director & Global CFO |
Mr. Rajesh V Desai | Ind. Non-Executive Director |
Dr. Brian W Tempest | Ind. Non-Executive Director |
Mr. Dipankar Bhattacharjee | Ind. Non-Executive Director |
Mr. Bernard Munos | Ind. Non-Executive Director |
Mr. Sridhar Gorthi | Ind. Non-Executive Director |
Mrs. Vijayalakshmi Iyer | Ind. Non-Executive Director |
Mr. D R Mehta | Ind. Non-Executive Director |
Ms. Saira Ramasastry | Ind. Non-Executive Director |
Mrs. B E Saldanha | Non Executive Director |
Glenmark Pharmaceuticals Forecast
Price Estimates
2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)
Glenmark Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-14 | Quarterly Results | |
2024-05-24 | Audited Results & Final Dividend | |
2024-02-14 | Quarterly Results | |
2023-11-10 | Quarterly Results | |
2023-08-11 | Quarterly Results |
Glenmark Pharmaceuticals FAQs
What is Share Price of Glenmark Pharmaceuticals ?
Glenmark Pharmaceuticals share price is ₹1,636 As on 21 September, 2024 | 04:15
What is the Market Cap of Glenmark Pharmaceuticals ?
The Market Cap of Glenmark Pharmaceuticals is ₹46187.2 Cr As on 21 September, 2024 | 04:15
What is the P/E ratio of Glenmark Pharmaceuticals ?
The P/E ratio of Glenmark Pharmaceuticals is -35.2 As on 21 September, 2024 | 04:15
What is the PB ratio of Glenmark Pharmaceuticals ?
The PB ratio of Glenmark Pharmaceuticals is 5.9 As on 21 September, 2024 | 04:15